Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice

Journal of Virology

Volumn 73, Issue 9, 1999, Pages 7099-7107

  Tripp, Ralph A ^a,c   Moore, Deborah ^a   Jones, Les ^a   Sullender, Wayne ^b   Winter, Jorn ^a   Anderson, Larry J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EOSINOPHILIA; FEMALE; HELPER CELL; IMMUNE RESPONSE; INFLAMMATION; LUNG INFECTION; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION;

EID: 0032816155     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.9.7099-7107.1999     Document Type: Article

References (38)

1. Alwan, W. H., W. J. Kozlowska, and P. J. Openshaw. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179:81-89.
2. Alwan, W. H., F. M. Record, and P. J. Openshaw. 1993. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J. Immunol. 150:5211-5218.
3. Bembridge, G. P., R. Garcia-Beato, J. A. Lopez, J. A. Melero, and G. Taylor. 1998. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. J. Immunol. 161: 2473-2480.
4. Chanock, R. M., R. H. Parrott, M. Connors, P. L. Collins, and B. R. Murphy. 1992. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics 90: 137-143.
5. Chin, J., R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainftuenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89: 449-463.
6. Connors, M., N. A. Giese, A. B. Kulkarni, C. Y. Firestone, H. C. Morse III, and B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:5321-5325.
7. Crowe, J. E., Jr., P. T. Bui, C.-Y. Firestone, M. Connors, W. R. Elkins, R. M. Chanock, and B. R. Murphy. 1996. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J. Infect. Dis. 173:829-839.
8. Crowe, J. E., Jr., P. T. Bui, W. T. London, A. R. Davis, P. P. Hung, R. M. Chanock, and B. R. Murphy. 1994. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691-699.
9. Dudas, R. A., and R. A. Karron. 1998. Respiratory syncytial virus vaccines. Clin. Microbiol. Rev. 11:430-439.
10. Fixler, D. E. 1996. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatri. Cardiol. 17:163-168.
11. Graham, B. S., G. S. Henderson, Y. W. Tang, X. Lu, K. M. Neuzll, and D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040.
12. Hancock, G. E., D. J. Speelman, K. Heers, E. Bortell, J. Smith, and C. Cosco. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:7783-7791.
13. Hussell, T., C. J. Baldwin, A. O'Garra, and P. J. Openshaw. 1997. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur. J. Immunol. 27:3341-3349.
14. Hussell, T., U. Khan, and P. Openshaw. 1997. IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness. J. Immunol. 159:328-334.
15. Hussell, T., and P. J. Openshaw. 1998. Intracellular IFN-g expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J. Gen. Virol. 79:2593-2601.
16. Johnson, T. R., J. E. Johnson, S. R. Roberts, G. W. Wertz, R. A. Parker, and B. S. Graham. 1998. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72:2871-2880.
17. Juhasz, K., S. S. Whitehead, P. T. Bui, J. M. Biggs, J. E. Crowe, C. A. Boulanger, P. L. Collins, and B. R. Murphy. 1997. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:5814-5819. (Erratum, 71:8953.)
18. Karron, R. A., D. A. Buonagurio, A. F. Georgiu, S. S. Whitehead, J. E. Adamus, M. L. Clements-Mann, D. O. Harris, V. B. Randolph, S. A. Udem, B. R. Murphy, and M. S. Sidhu. 1997. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. USA 94:13961-13966.
19. Llan, R. H., J. D. Freeman, D. L. Mager, and F. Takei. 1998. Role of conserved glycosylation site unique to marine class I MHC in recognition by Ly-49 NK cell receptor. J. Immunol. 161:2301-2306.
20. McIntosh, K., and J. M. Fishaut. 1980. Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus. Progr. Med. Virol. 26:94-118.
21. Oien, N. L., R. J. Brideau, D. R. Thomsen, F. L. Homa, and M. W. Wathen. 1993. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity. Vaccine 11:1040-1048.
22. Openshaw, P. J. 1995. Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am. J. Respir. Crit. Care Med. 152:S59-S62.
23. Openshaw, P. J., S. L. Clarke, and F. M. Record. 1992. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:493-500.
24. Parrott, R. H., H. W. Kim, C. D. Brandt, and R. M. Chanock. 1975. Potential of attenuated respiratory syncytial virus vaccine for infants and children. Dev. Biol. Stand. 28:389-399.
25. Sparer, T. E., S. Matthews, T. Hussell, A. J. Rae, B. Garcia-Barreno, J. A. Melero, and P. J. Openshaw. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1921-1926.
26. Spender, L. C., T. Hussell, and P. J. Openshaw. 1998. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. J. Gen. Virol. 79:1751-1758.
27. Srikiatkhachorn, A., and T. J. Braciale. 1997. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186:421-432.
28. Srikiatkhachorn, A., and T. J. Braciale. 1997. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71: 678-685.
29. Sullender, W. 1995. Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus. Virology 209:70-79.
30. Tripp, R. A., and L. J. Anderson. 1998. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine. J. Virol. 72:8971-8975.
31. Tripp, R. A., S. Hou, A. McMickle, J. Houston, and P. C. Doherty. 1995. Recruitment and proliferation of CD8+ T cells in respiratory virus infections. J. Immunol. 154:6013-6021.
32. Tripp, R. A., S. R. Sarawar, and P. C. Doherty. 1995. Characteristics of the influenza virus-specific CD8+ T cell response in mice homozygous for disruption of the H-21Ab gene. J. Immunol. 155:2955-2959.
33. Tristram, D. A., R. C. Welliver, C. K. Mohar, D. A. Hogerman, S. W. Hildreth, and P. Paradiso. 1993. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167:191-195.
34. Waris, M. E., C. Tsou, D. D. Erdman, D. B. Day, and L. J. Anderson. 1997. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J. Virol. 71:6935-6939.
35. Weibel, R. E., J. Stokes, Jr., M. B. Leagus, C. C. Mascoli, and M. R. Hilleman. 1966. Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine. Am. Rev. Respir. Dis. 94:362-379.
36. Wertz, G. W., E. J. Stott, K. K. Young, K. Anderson, and L. A. Ball. 1987. Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J. Virol. 61:293-301.
37. Whitehead, S. S., K. Juhasz, C. Y. Firestone, P. L. Collins, and B. R. Murphy. 1998. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J. Virol. 72:4467-4471.
38. Yang, Z., R. Delgado, L. Xu, R. F. Todd, E. G. Nabel, A. Sanchez, and G. J. Nabel. 1998. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279:1034-1037.